Publications by authors named "David Dayde"

Claim this Profile
I
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
Pauline Corbaux, Gilles Freyer, Olivier Glehen, Benoît You, Naoual Bakrin, David Dayde

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a screening and prevention procedure for risks associated with dysphagia in older patients in geriatric units: the DYSPHAGING pilot study protocol.
Olivier Durlach, Stéphanie Tripoz-Dit-Masson, Nicolas Massé-Deragon, Fabien Subtil, Zeinabou Niasse-Sy, David Dayde

BMJ Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors associated with day-30 mortality in patients over 60 years old admitted in ICU for severe COVID-19: the Senior-COVID-Rea Multicentre Survey protocol.
Claire Falandry, Amélie Malapert, Mélanie Roche, Fabien Subtil, Julien Berthiller, David Dayde

BMJ Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cultural and Ethical Barriers to Cancer Treatment in Nursing Homes and Educational Strategies: A Scoping Review.
Cynthia Filteau, Arnaud Simeone, Christine Ravot, David Dayde, Claire Falandry

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol.
Mélanie Roche, Christine Ravot, Amélie Malapert, Sophie Paget-Bailly, Charlène Garandeau, David Dayde

BMJ Open· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZEBRA cell-penetrating peptide as an efficient delivery system in Candida albicans.
Roberta Marchione, David Daydé, Jean-Luc Lenormand, Muriel Cornet

Biotechnol J· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.
David Daydé, David Ternant, Marc Ohresser, Stéphanie Lerondel, Sabrina Pesnel

Blood· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.
Severine Loisel, Marc Ohresser, Marc Pallardy, David Daydé, Christian Berthou

Crit Rev Oncol Hematol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis